Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company”…
Month: August 2022
Verona Pharma plc Announces Proposed Underwritten Public Offering
LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)…
Certara Reports Second Quarter 2022 Financial Results
Biosimulation software and services fuel second quarter growth PRINCETON, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE)…
Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) today announced…
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,”…
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
– Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced…
Codex DNA Reports Second Quarter 2022 Financial Results
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB),…
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing…
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with…
Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program
– Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more…
Seer Reports Second Quarter 2022 Financial Results
Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power…
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30…
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received…
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development…
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks…
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and…
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell…
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of…